Early treatment failure · adults with basal cell carcinoma of the skin
MAL‐PDT probably leads to higher early treatment failure compared with surgical excision (moderate certainty).
1 finding from 1 review
Recurrence · adults with basal cell carcinoma of the skin
Imiquimod cream probably leads to lower recurrence at 3 years compared with MAL‐PDT (moderate certainty).
2 findings from 1 review
Cosmesis · adults with basal cell carcinoma of the skin
Imiquimod cream showed no clear difference in cosmetic outcome (excellent/good) compared with MAL‐PDT (moderate certainty).
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin
Imiquimod cream probably leads to lower pain (moderate/severe) compared with MAL‐PDT (moderate certainty).
1 finding from 1 review
Early treatment failure · adults with basal cell carcinoma of the skin
Imiquimod cream showed no clear difference in early treatment failure compared with MAL‐PDT (moderate certainty).
1 finding from 1 review
Cosmesis · adults with basal cell carcinoma of the skin
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Pain · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early treatment failure · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · adults with basal cell carcinoma of the skin
Imiquimod probably leads to higher recurrence at 3 years compared with surgical excision (moderate certainty).
2 findings from 1 review
Cosmetic outcome (good/excellent) · adults with basal cell carcinoma of the skin
Imiquimod may leads to higher cosmetic outcome (good/excellent) compared with surgical excision (low certainty).
1 finding from 1 review
Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin
Imiquimod showed no clear difference in pain (moderate/severe) compared with surgical excision (low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement of quality of life · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks) · people with mycosis fungoides
Bexarotene + PUVA showed no clear difference in common adverse effects ‐ Photosensitivity (Time point of… compared with PUVA alone (low certainty).
1 finding from 1 review
Complete response · people with mycosis fungoides
Bexarotene + PUVA showed no clear difference in complete response (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).
1 finding from 1 review